Advertisement

TheBodyPRO.com Covers CROI 2016

News

48-Week Results for Doravirine Compared to Efavirenz

March 22, 2016

Phase 2 results in treatment naive patients using doravirine (MK-1439) -- an NNRTI in development with Merck -- were presented in a poster from José Gatell from Barcelona Hospital and colleagues.1

This was a randomised, double-blind, placebo controlled phase 2 dose finding study in two parts. In part 2, new patients started using the selected 100 mg doravirine dose. All participants were treatment naive and used tenofovir DF/FTC as background NRTIs.

Combined 48 week data included 42 people randomised to the 100 mg once-daily dose in part one of the study plus 66 participants who were added in part two (n=108), compared with 109 control patients randomised to efavirenz.

Advertisement
Baseline demographics included ~90% men, 75% white, with mean age 35 (range 19-67) years and median CD4 count and viral load of approximately 425 cells/mm3 (range 92 to 1121) and 2.6 log copies/mL (range 2.6 to 6.7).

At week 48, viral suppression to <40 copies/mL was reported for 77.8% vs 78.7% of the doravirine vs efavirenz groups respectively, (difference -1.1%; 95%CI -12.2 to +10.0). There were slightly fewer discontinuations in the doravirine group (12% vs 14.7%) which included fewer discontinuations related to side effects (2.8% vs 5.5%).

In patients with baseline viral load <100,000 copies/mL approximately 87% in each group reached <40 copies/mL at week 48 but greater suppression was reported for the efavirenz group for those starting with viral load >100,000 copies/mL (74% vs 84%). Both groups reported 91% rates using a <200 copies/mL test.

There were few laboratory abnormalities greater than grade 2 but lipids, liver enzymes and lipase generally favoured the doravirine group and abnormal glucose fasted occured slightly more in the doravirine group (3.2 % va 1.1%).

Ongoing studies include as part of a single tablet, fixed dose combination with generic NRTIs: doravirine/tenofovirDF/3TC.2


References

  1. Gatell JM et al. Doravirine 100mg QD vs efavirenz +TDF/FTC in ART-naive HIV+ patients: week 48 results. 23rd CROI, 22-25 February 2016, Boston. Poster abstract 470.
    www.croiconference.org/sessions/doravirine-100mg-qd-vs-efavirenz-tdfftc-art-naive-hiv-patients-week-48-results (Abstract)
    www.croiconference.org/sites/default/files/posters-2016/470.pdf (PDF poster)
  2. Clinicaltrials.gov listing. Effects of switching from ATRIPLA (efavirenz, tenofovir, emtricitabine) to MK-1439A (doravirine, tenofovir, lamivudine) in virologically-suppressed participants (MK-1439A-028)
    https://clinicaltrials.gov/ct2/show/NCT02652260



Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.